Welcome to our dedicated page for Xenon Pharmaceuticals news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceuticals stock.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) is a pioneering biopharmaceutical company headquartered in Vancouver, British Columbia. Focused on neurology, Xenon leverages its proprietary discovery platform, termed 'extreme genetics', to develop innovative medications. The company’s approach involves studying families with severe phenotypes to identify single-gene defects, which offer insights into human biology and serve as potential drug targets.
Xenon’s development pipeline targets a range of neurological disorders, particularly epilepsy and depression. The flagship product, XEN1101, is a potent, selective potassium channel opener currently in various phases of clinical trials for epilepsy and major depressive disorder (MDD). Xenon has ongoing Phase 3 trials for XEN1101 in focal onset seizures (X-TOLE2, X-TOLE3) and primary generalized tonic-clonic seizures (X-ACKT). The drug has shown promising efficacy in reducing seizures and improving quality of life in long-term extension studies.
Additionally, Xenon is exploring XEN1101's potential in treating MDD, with a Phase 3 program expected to begin in 2024. Recent interim data from the X-NOVA Phase 2 trial revealed significant improvements in depression symptoms, supporting further development for this indication. Xenon’s pre-clinical work includes investigations into Nav1.1 and Nav1.7 potentiators for various neurological conditions.
Key developments include a partnership with Neurocrine Biosciences to develop XEN901 (NBI-921352) for epilepsy. Xenon's financial stability, robust clinical pipeline, and strategic collaborations position it for continued growth and innovation in neurology-focused therapeutics.
Recent Achievements:
- Strong presence at AES 2023 with multiple presentations on XEN1101
- Presented new data from the Phase 2b X-TOLE trial demonstrating significant seizure freedom rates
- Expanded open-label extension study collecting over 500 patient years of data
- Announced positive topline results from X-NOVA Phase 2 trial for MDD
- Ongoing collaboration with Icahn School of Medicine for additional MDD studies
For more updates and detailed information, visit the official website.
Xenon Pharmaceuticals has initiated its Phase 3 program for XEN1101 by launching the X-TOLE2 clinical trial, targeted at treating adult patients with focal epilepsy. This follows positive Phase 2b results and successful discussions with the FDA regarding trial design. The X-TOLE2 and its parallel study, X-TOLE3, aim to evaluate XEN1101's efficacy as an adjunctive treatment, involving approximately 360 patients each. Successful outcomes could lead to a New Drug Application submission. The program reflects Xenon's commitment to addressing unmet medical needs in epilepsy treatment.
Xenon Pharmaceuticals (Nasdaq:XENE) announced it will release its third quarter 2022 financial results on November 8, 2022, after U.S. markets close. The company is focused on developing innovative therapies for neurological disorders, particularly epilepsy. A live conference call and audio webcast will take place at 4:30 PM ET on the same day. Investors can register for participation to receive dial-in details. Xenon is committed to addressing high unmet medical needs in the neurology sector.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will participate in one-on-one investor meetings and a fireside chat at the 17th Annual Wells Fargo Securities Healthcare Conference from September 7-9, 2022. The fireside chat is scheduled for September 8, 2022, from 11:35 am to 12:05 pm ET, featuring President and CEO Ian Mortimer and CCO Chris Von Seggern as presenters. A webcast will be available in the 'Investors' section of Xenon's website, with replays posted afterward. Xenon focuses on developing therapeutics for neurological disorders, particularly epilepsy.
Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q2 2022 results, highlighting a cash balance of $788.2 million and a cash runway extended into 2026 following a successful equity offering. The company plans to initiate the XEN1101 Phase 3 program, including the 'X-TOLE2' trial, in the second half of 2022. Recent analyses show XEN1101 rapidly reduced focal onset seizure frequency in prior trials. However, total revenue fell to $0.5 million from $2.2 million year-over-year, contributing to a net loss of $31.2 million, up from $22.1 million in Q2 2021.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will report its Q2 2022 financial and operational results after U.S. markets close on August 9, 2022. The conference call and webcast will be held at 4:30 PM Eastern Time the same day, providing updates on the company’s performance in developing therapeutics for neurological disorders, focusing on epilepsy. Investors can access the live webcast on Xenon's website, with a replay available afterward. The announcement underscores Xenon's commitment to addressing high unmet medical needs in neurology.
Xenon Pharmaceuticals (Nasdaq:XENE) will participate in the William Blair Biotech Focus Conference 2022 on July 12-13, 2022, in New York, NY. The company is focused on developing innovative therapeutics for neurological disorders, particularly in the area of epilepsy. A webcast of their fireside chat presentation will be available on their Investors section of the website. Xenon aims to address significant unmet medical needs through its clinical-stage product pipeline.
Xenon Pharmaceuticals has successfully closed its underwritten public offering of 9,098,362 common shares, raising approximately $287.5 million in gross proceeds. The offering included 1,229,508 shares from the underwriters’ option and 327,868 pre-funded warrants. Each common share was priced at $30.50, while pre-funded warrants were offered at $30.4999 with an exercise price of $0.0001. Major underwriters for this offering included Jefferies, J.P. Morgan, SVB Securities, and Stifel.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has priced its underwritten public offering of 7,868,854 common shares at $30.50 per share, alongside pre-funded warrants for 327,868 shares at $30.4999 each. The anticipated gross proceeds are approximately $250 million. An additional option allows underwriters to purchase up to 1,229,508 shares within 30 days. The offering is projected to close around June 27, 2022, subject to customary conditions. These transactions are part of an existing shelf registration statement with the SEC, filed on October 4, 2021.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announced an underwritten public offering of its common shares and pre-funded warrants to purchase common shares. The offering is part of its existing shelf registration statement, and underwriters may purchase an additional 15% of shares at the public offering price within 30 days. The offering is subject to market conditions, and completion is uncertain.
Jefferies, J.P. Morgan, SVB Securities, and Stifel are the joint book-running managers for this offering.
Xenon Pharmaceuticals (Nasdaq:XENE) announced significant efficacy results from the Phase 2b X-TOLE trial of XEN1101, showing rapid reduction in focal onset seizures within one week across all doses. The median percent reduction was 55.4% for the 25 mg dose (p<0.001), with continued effectiveness in the open-label extension (OLE) phase, exceeding 70% reduction at 3 months and 80% at 12 months. The company plans to extend the OLE from three to five years. XEN1101 has shown a favorable safety profile, aligning with other anti-seizure medications.
FAQ
What is the current stock price of Xenon Pharmaceuticals (XENE)?
What is the market cap of Xenon Pharmaceuticals (XENE)?
What does Xenon Pharmaceuticals specialize in?
What is the focus of Xenon’s proprietary discovery platform?
What is XEN1101?
What are the recent achievements of Xenon Pharmaceuticals?
Who are Xenon’s strategic partners?
What are Xenon’s key products in the pipeline?
What is the status of the XEN1101 epilepsy trials?
How can I contact Xenon Pharmaceuticals for investor information?
Where is Xenon Pharmaceuticals headquartered?
What is the significance of Xenon’s pre-clinical work?
